Cohort (CHRT) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Cohort £12.98, price £11.80, upside +10.0%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cohort for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range £3.66 – £17.22 · fair‑value band £9.74 – £16.23 · the £11.80 price screens below the £12.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Cohort in your weekly email
Every Wednesday you see whether Cohort is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cohort plc provides various products and services in defense, security, and related markets in the United Kingdom, Germany, Portugal, Australia, North and South America, Asia Pacific, Africa, and other European countries. It operates through Communications and Intelligence; and Sensors and Effectors segments.
Show more
Cohort plc provides various products and services in defense, security, and related markets in the United Kingdom, Germany, Portugal, Australia, North and South America, Asia Pacific, Africa, and other European countries. It operates through Communications and Intelligence; and Sensors and Effectors segments. The company offers chess dynamic, a surveillance and fire control which provides bespoke solutions for land and maritime domains; and combat systems. It also provides integrated command, control, and communications systems for warships and submarines; tactical radio, vehicle intercoms, field communications, and networking software and equipment; sonar systems and underwater communications; and electronic and surveillance technology services. In addition, the company offers training and simulation; digital forensics; research, advice, and support services; sonar, radar, and visual for land and sea domains; and intelligent transport systems. It offers its products and services for customers in the cyber and information, land, maritime, joint and strategic, air and space, and other markets. Cohort plc was incorporated in 2006 and is headquartered in Reading, the United Kingdom.
Stock analysis
Cohort (CHRT) currently trades at £11.80, while our model-based Fair Value estimate is £12.98, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of £12.84 per share, and 8 of the 26 models we run sit above the £11.80 price.
Bear case: the Dividend Discount group reads lowest at £1.81, and 18 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: £9.74 (bear) to £16.23 (bull), the price of £11.80 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Industrials sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Cohort reported revenue of £270M in FY2025 versus £143M in FY2021, a compound +17.2%/yr. Reported net income was £19.2M in FY2025, compounding +37.0%/yr from FY2021.
Key figures
Market cap 593M GBX · P/E ratio 29.5 · P/S ratio 2.10 · EPS (TTM) £0.4000 · Dividend yield 1.4% · Net margin 7.1% · Return on equity 13.5% · Return on assets (EBIT) 6.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 20% below its 52-week high and 32% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −20% fair-value upside, at 10%, CHRT screens cheaper than that median.
Fair Value models
Bear £9.74Fair Value £12.98Bull £16.23
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (£0.2310 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+33.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.6%
Start year 2020 (pandemic). Over 10 years: +10.5% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+26.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.4%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.27% vs 12%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 10%
2025 sits 59% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +1.2% a year for the price and +5.6% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Aerospace & Defense · 228 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside+10% · Top 25%
Profitability
Return on equity (TTM)14% · Above median
Return on assets4% · Above median
Net margin (TTM)7% · Below median
Operating margin (TTM)6% · Below median
Growth and dividend
Revenue growth9% · Below median
Dividend yield (TTM)1.4% · Above median
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Aerospace & Defense median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cohort Fair Value". https://www.fairvalue-calculator.com/stock/CHRT
Frequently asked questions
Is Cohort (CHRT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of £12.98 versus a price of £11.80, about +10% upside (undervalued).
What is the fair value of CHRT?
Our model-based fair value for Cohort is £12.98 (as of Sep 23, 2026), built from audited fundamentals. The current price: £11.80.
What is the quality score of CHRT?
Cohort has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cohort (CHRT)?
Our model-based price target is the fair value of £12.98 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario £9.74, optimistic scenario £16.23. It is a calculation from audited fundamentals, not an analyst target.
What is the Cohort stock forecast for 2026?
Our models put fair value at £12.98, about +10% upside versus a price of £11.80 (undervalued). Cautious scenario £9.74, optimistic scenario £16.23. The calculation is refreshed regularly with new filings.
What is the revenue of Cohort (CHRT)?
Cohort reported trailing-twelve-month revenue of about £281M (latest available figure, as of Sep 23, 2026).
Does Cohort pay a dividend?
Cohort currently shows a dividend yield of about 1.43% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Cohort (CHRT)?
For today's price to be fair in a discounted-cash-flow model, Cohort would have to grow free cash flow by +3.6 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.6 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of CHRT use?
Our models discount Cohort at 10.3 %: a base by market capitalisation (small), damped by beta 0.34, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cohort that is +3.6 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Cohort (CHRT) delivered so far?
Over the past 5 years revenue at Cohort grew +15.6 % a year. The price currently implies +3.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Cohort (CHRT) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into Cohort (+3.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cohort (CHRT)?
The free-cash-flow yield on the price is 7.40 %: that much free cash flow Cohort produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cohort (CHRT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cohort it is £12.98 per share (as of Sep 23, 2026), against a price of £11.80. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Cohort stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CHRT trades below its calculated fair value: price £11.80, fair value £12.98, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHRT?
No. The price is what the market pays today (£11.80); the fair value is what the company's own numbers justify (£12.98). For Cohort the two are £1.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cohort worth?
The market values Cohort at about 593M GBX (market capitalisation, as of Sep 23, 2026). Per share that is £11.80; our models calculate a fair value of £12.98 per share.
What do the bullish and bearish scenarios say about CHRT?
Our models span a range for Cohort: cautious scenario £9.74, base £12.98, optimistic £16.23 per share (as of Sep 23, 2026, price £11.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CHRT?
Cohort trades at a price-to-earnings ratio of 29.5 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £12.98 is built from several models across several years. Other multiples: P/B 5.0, P/S 2.8, EV/EBITDA 22.4.
How solid is the balance sheet of Cohort (CHRT)?
Balance-sheet figures for Cohort (as of Sep 23, 2026): return on equity 13.5%, debt of 0.20 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is CHRT from its 52-week high?
Cohort trades at £11.80, about 20% below its 52-week high of £14.74 and 32% above the low of £8.92 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of £12.98 is for.
Which stocks are comparable to Cohort?
From the same area (Industrials) we also value General Electric Company, RTX Corporation, Airbus SE, Safran SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cohort stock attractive at the current price?
The data as of Sep 23, 2026: price £11.80, calculated fair value £12.98 (+10%), Quality Score 48/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHRT calculated?
We run Cohort through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £12.98, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Cohort currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cohort (CHRT)?
The closing price on Sep 23, 2026 was £11.80. Our model-based fair value is £12.98, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cohort right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Cohort (CHRT) come from?
Earnings per share at Cohort grew +10.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.6 %, EBIT margin +4.8 %, tax rate −1.5 %, residual (interest, one-offs) −2.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Cohort
How large is the market capitalisation of Cohort (CHRT)?
The market capitalisation of Cohort is 593M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cohort (CHRT)?
The price-to-sales ratio of Cohort is 2.10 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cohort (CHRT)?
Earnings per share at Cohort are £0.4000 (price ÷ EPS = P/E 29.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cohort (CHRT)?
The dividend yield of Cohort is 1.4% (payout 42.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cohort (CHRT)?
The net margin of Cohort is 7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cohort (CHRT)?
The return on equity (ROE) of Cohort is 13.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cohort (CHRT)?
On an EBIT basis the return on assets of Cohort is 6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cohort (CHRT)?
The operating margin of Cohort is 5.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cohort (CHRT)?
Revenue at Cohort is growing +8.9% versus a year earlier (3y avg +25.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cohort (CHRT)?
Earnings per share at Cohort are growing −24.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Cohort (CHRT) carry?
The net debt of Cohort is 4.2M GBX (fiscal year 2025, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cohort in the live analysis
One click puts Cohort on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
